India, Feb. 12 -- For Travere Therapeutics Inc. (TVTX), the year so far has been nothing short of remarkable, with its shares hitting new highs, driven by the success of its oral kidney disease drug, Filspari.
Filspari indicated to slow kidney function decline in adults with a kidney disease called primary immunoglobulin A nephropathy, who are at risk of their disease getting worse, has been on the U.S. market since February 2023. The drug, which was approved under the accelerated approval pathway, was given full FDA approval last September. The drug is also marketed in Europe for the treatment of IgAN by the company's partner CSL Vifor.
IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis worldwide, often leading to pr...